Cardiac implants market is estimated to be valued at USD 48,862 Mn in 2026 and is expected to reach USD 83,490 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 8.0% from 2026 to 2033.
Rising prevalence of cardiovascular diseases such as arrhythmias, heart failure, and myocardial infarction, demand for cardiac implants including pacemakers, ICDs, CRT devices, stents, and heart valves has been increasing recently. Furthermore, increasing awareness of advanced cardiac care and growing adoption of minimally invasive procedures have further boosted market growth. Technological innovations, such as leadless pacemakers, wireless monitoring devices, and transcatheter heart valves, are attracting the attention of hospitals and specialty clinics to adopt these solutions.
|
Current Events |
and its impact |
|
Regulatory Harmonization and Approval Processes |
|
|
Advanced Material Science and Biocompatibility Innovations |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Based on device type, pacemaker devices are estimated to account for the highest market share of 42% in 2026, owing to their importance in controlling arrhythmias and increasing patient survival rates. Pacemakers are used to control abnormal heart rhythms, and rhythm management is essential for patients suffering from bradycardia and conduction disorders.
For instance, in October 2025, Abbott announced the commercial availability of its dual chamber leadless pacemaker system that can synchronize two small pacemakers inserted inside the patient’s heart.
Based on applications, the arrhythmias segment is projected to capture the highest market share of 33% by the year 2026, primarily due to the rise in instances of arrhythmia, including atrial fibrillation, ventricular tachycardia, and sudden cardiac death. In addition, awareness about the early diagnosis and the requirement for constant monitoring has also led to an increased demand for the implantation of pacemakers, ICDs, and CRTs.
For instance, in July 2025, Johnson & Johnson MedTech launched the world's first pulsed field ablation system, the VARIPULSE™ Platform, integrated with CARTO™ 3 mapping for treating atrial fibrillation, which is a common arrhythmia.
Based on end users, the hospitals segment is anticipated to generate the maximum market share of 55% by 2026 due to advanced facilities for surgeries, availability of skilled cardiologists, and comprehensive services for heart conditions. Similarly, hospitals offer full-service solutions to patients and thus remain the first choice for procedures and treatments.
For instance, in March 2025, the Melrose Wakefield Hospital, located in Massachusetts, reported the successful implementation of a leadless atrial pacemaker procedure through its cardiac catheterization laboratory.

To learn more about this report, Download Free Sample
North America is likely to account for the largest share of 40% in the cardiac implants market by 2026, due to various factors such as advanced healthcare infrastructure, high prevalence of cardiovascular diseases, strong reimbursement policies, and higher adoption of innovative implantable devices like leadless pacemakers, ICDs, and CRT systems.
For instance, in January 2026, Mission Hospital in Western North Carolina expanded its cardiac care services to install a new leadless pacemaker system with the aim of helping patients when their hearts beat slowly or irregularly, and to reduce procedural discomfort and recovery times.
The Asia Pacific region is expected to be the fastest-growing market for cardiac implants due to the rising incidence of cardiovascular diseases, rising healthcare spending, expanding infrastructure, and improving knowledge of advanced treatment facilities available. Increasing numbers of new hospitals and cardiac institutions are using minimally invasive cardiac implant devices, leading to improved patient care and hence expanding the cardiac implants market.
For instance, in October 2025, Apollo Hospitals Chennai completed its first leadless dual-chamber AVEIR pacemaker procedure, highlighting the rapid adoption of advanced cardiac device technology in the Asia Pacific hospital segment.
The U.S. cardiac implants market is experiencing a high growth rate, primarily due to the high incidence rate of cardiovascular diseases, advanced healthcare facilities, and the increased use of cutting-edge devices such as leadless Pacemakers, ICDs, and CRTs in the USA. Furthermore, various hospitals and cardiovascular centers are investing heavily in minimally invasive cardiovascular implant devices.
For instance, in January 2026, the Allina Health Minneapolis Heart Institute in Minnesota became one of the first programs in the Upper Midwest to offer the OmniaSecure defibrillation lead, which is thinner and more flexible to help optimize ICD outcomes.
Canada’s cardiac implants market is growing as a result of favorable public healthcare policies in the country. Additionally, growing heart health awareness and hospitals adopting the latest technology in heart treatments, such as pacemakers and defibrillators, are also boosting this market.
For instance, in February 2025, London Health Sciences Centre in Ontario became the first hospital in Canada to implant a cutting-edge extravascular ICD, marking a significant step in the adoption of minimally invasive cardiac devices in the country.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 48,862 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.0% | 2033 Value Projection: | USD 83,490 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Abbott Laboratories, B. Braun Melsungen AG, Boston Scientific Corporation, Edwards Lifesciences Corporation, Meril Life Sciences Pvt. Ltd. , Lepu Medical Technology (Beijing) Co., Ltd., BIOTRONIK SE & Co. KG, OSYPKA MEDICAL, Pacetronix.com, Vitatron, Terumo Corporation, Cordis, MicroPort Scientific Corporation. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Increasing incidence of cardiac-related diseases such as arrhythmias, heart failure, and myocardial infarctions, among others, is fueling the increased need for cardiac implants worldwide. Various hospitals and cardiac centers are increasingly using advanced cardiac implants such as pacemakers, ICDs, CRT, and leadless pacemakers for the management and treatment of cardiac rhythm-related disorders among their patients.
The market is expected to show high growth potential through the introduction of next-generation cardiac implants such as leadless pacemakers, extravascular ICDs, smart devices, etc., in the market. Additionally, the hospital industry can enhance these advanced technologies to increase the usage of next-generation cardiac implantable to enhance security, minimize procedural issues, and improve overall clinical outcomes. The device miniaturization, efficiency, and connectivity are expected to increase the potential of this market to grow in North America, Europe, and Asia Pacific.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients